The effects of vitamin K2 supplementation on the progression of CAC has not yet been studied in humans in a controlled clinical trial.
A new clinical study will be performed on NattoPharma ASA’s (Lysaker, Norway) MenaQ7 natural vitamin K2, the company announced. The company is cosponsoring the study, which will investigate the effects of natural vitamin K2 on coronary arterial calcification (CAC).
The company says that while earlier studies in humans demonstrate that a high dietary intake of vitamin K is associated with lower cardiovascular risk and a lesser degree of coronary artery calcification, the effects of vitamin K2 supplementation on the progression of CAC has not yet been studied in humans in a controlled clinical trial.
The 24-month, 180-person study will be performed in cooperation with the Dutch Heart Foundation, at the department of internal medicine of the Maastricht University Medical Center in the Netherlands. The double-blind, placebo-controlled, randomized trial will address whether vitamin K2 supplementation can slow the progression of CAC.